Zealand Pharma finishes phase III enrollment
All patients have been found for a phase III study of a potential hyperinsulinism treatment for children, reports Zealand Pharma.
by marketwire, translated by daniel pedersen
Zealand Pharma has announced that recruitment for an upcoming phase III study with a drug candidate, dasiglucagon, designed to treat infants up to 12 months of age with congenital hyperinsulinism (CHI), has been completed, a company press release reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma finds all patients for phase III study
For subscribers
Zealand Pharma enters US partnership over pump system
For subscribers
.jpg&w=384&q=75)
